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Summary
Colorectal cancer (CRC) is one of the most common cancers and one of the leading causes 
of cancer death in the Western world. The disease arises from the accumulation of mutations in 
oncogenes, tumor suppressor genes and mismatch repair genes during progression from normal 
colon epithelium to adenoma and metastatic carcinoma. The majority of colorectal cancers arise 
in sporadic form. About one-third of patients with CRC have a family history of cancer and ele-
vated risk for this malignant disease. However, only 5% of CRC arise from a germline mutation in 
high penetrant genes, adenomatous polyposis coli (APC) gene and DNA mismatch repair (MMR) 
genes. The most common hereditary CRC syndrome is Lynch syndrome defined by hereditary 
germline mutations in one the of MMR genes. The term hereditary non-polyposis colorectal 
cancer (HNPCC), previously used interchangeably with Lynch syndrome, now refers to a broader 
spectrum of familial CRC disorders that can mimic some clinical features of Lynch syndrome, 
but without germline mutations in MMR genes characteristic for Lynch syndrome. Distinguishing 
between the HNPCC disorders is important for clinicians, as the approach to surveillance for pa-
tients and their family members differs according to risk for CRC associated with each syndrome.
This mini review will give some information about the most frequent molecular genetics 
changes in sporadic and hereditary colorectal cancer and its molecular stratification due to its 
heredity, somatic mutations and microsatellite instability.
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Colorectal cancer (CRC) is one of the most common cancers and represents the 
third most diagnosed cancer in both men and women. Despite advances in surgery, 
chemotherapy and screening it is still one of the leading causes of cancer related 
death in the Western world [1].
Of all human cancers, the molecular genetic alterations in colorectal cancer are 
best understood. The disease arises from the accumulation of mutations in oncoge-
nes, tumor suppressor genes and mismatch repair (MMR) genes during progression 
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from normal colorectal epithelium to adenoma and metastatic carcinoma (Figure 1) 
[2]. Colorectal cancer is a genetic disease that might be influenced by the local colo-
rectal environment, individuals’s genetic profile as well as by hereditary germline 
mutations [3,4].
The majority of colorectal cancers (75-80%) arise in sporadic form without 
known contribution from germline mutations and only 20-25% of the patients have 
a family history of CRC. However, only 5% of CRC arise from a germline mutation 
in high penetrant genes, adenomatous polyposis coli (APC) gene (1%) and MMR 
genes (3-5%) while the remaining CRCs have a positive family history but cannot 
be categorized to any hereditary CRC syndrome. These familial CRC are caused by 
single nucleotide polymorphisms (SNP) in less penetrant genes such as cytokines. 
Many susceptibility loci have been identified, however, their value in CRC risk pre-
diction remains low [5,6].
The development of colorectal cancer is a multistep process caused by progre-
ssive accumulation of genetic and epigenetic changes that cause activation of on-
cogenes and/or inactivation of tumor suppressor genes. The earliest trigger is the 
mutation of the APC (Adenomatous Polyposis Coli) gene. Mutations in oncogenes 
(KRAS) and tumor suppressor genes (p53, DPC4) as well as mutations and epigene-
tic changes in MMR (MisMatch Repair) gene drive tumor towards malignant tran-
sformation and metastasis. [3,5,7-9].
Sporadic CRC can be divided into two groups: hypermutated (16% of sporadic 
CRC) and nonhypermutated (84% of sporadic CRC). The etiology of hypermutated 
tumors is largely driven by the presence of microsatellite instability (MSI) as a result 
of mutations in mismatch repair (MMR) genes, specifically somatic hypermethyla-
tion of hMLH1 gene. Nonhypermutated sporadic CRC is driven by mutations des-
cribed as adenoma carcinoma sequence including APC, KRAS and p53 gene muta-
tions. BRAF gene is most frequently mutated in hypermutated tumors than APC 
is mutated in both groups of sporadic CRC, what is in accordance with its role as a 
gatekeeper mutation in CRC [3,10-12]. The results of research studies also characte-
rized 3 molecular pathways that highlight CRC development and progression: MSI 
(wholly within the hypermutated group), chromosomal instability (CIN; wholly in 
the nonhypermutated group) and CpG island methylator phenotype (CIMP; within 
both the hypermutated and nonhypermutated group) [3].
The level and nature of inflammation in primary CRC may be complex, but the 
type, density and intratumor location of immune cells can predict patient survival, 
often better than classical staging [13]. This same inflammation has been associated 
with initiating alterations involving specific tetranucleotide microsatellite DNA 
sequences, termed “elevated microsatellite alterations at selected tetranucleotide 
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repeats” or EMAST caused by loss of the DNA MMR complex function due to a 
nucleus-to-cytosol shift of its component hMSH3 protein. EMAST can be identified 
in up to 60% of CRCs making this biomarker more common than MSI high (MSI-H) 
[14]. The presence of EMAST in primary CRCs predict advanced-stage disease in 
patients and is associated with poor survival over patients with EMAST negative 
CRC tumors. EMAST can modulate all 3 (MSI-H, CIN and CIMP) pathways in spo-
radic CRC tumorigenesis and is a biomarker linked to advanced, metastatic stage 
and poor survival in both groups, hypermutated and nonhypermutated sporadic 
colorectal cancer [15,16].
About one-third of patients with colorectal cancer have a family history of can-
cer but only 5% of all patients with CRC have identified hereditary mutations in 
genes that regulate growth processes in colonic cells. The most common hereditary 
CRC syndrome is Lynch syndrome identified and defined by hereditary germline 
mutations in one of the DNA mismatch repair (MMR) genes (MSH2, MLH1, MSH6, 
PMS2) and is transmitted in an autosomal dominant fashion [17]. Mismatch repair 
proteins form a complex that detects and corrects replication errors. A deregulated 
MMR system due to the mutations in MMR genes leads to accelerated accumulation 
of somatic mutations, often resulting in carcinogenesis. The two most commonly 
mutated MMR genes, MSH2 and MLH1, account for approximately 90% of muta-
tions found in Lynch syndrome patients, with the remaining 10-30% distributed 
equally in MSH6 and PMS2 [17-19].
Microsatellite instability (MSI) is the molecular marker of MMR genes mutati-
ons and DNA mismatch repair deficiency. Additionally, the use of immunohistoche-
mistry to detect expression of DNA MMR proteins in tumor tissue is highly compa-
rative to MMR function. The finding of MSI and/or absence of DNA MMR protein 
expression identifies that a tumor has lost DNA MMR function, and is the basis 
for differentiating familial CRC cases associated with Lynch syndrome from other 
HNPCC conditions [19-22].
The term hereditary non-polyposis colorectal cancer (HNPCC), previously used 
interchangeably with Lynch syndrome, now refers to a broader spectrum of fami-
lial CRC encompassing disorders that can mimic some clinical features of Lynch 
syndrome, but without germline mutations in MMR genes characteristic for Lynch 
syndrome. Distinguishing between the HNPCC disorders is important for clinici-
ans, as the approach to surveillance for patients and their family members differs 
according to risk for colonic and extracolonic cancers associated with each syndro-
me [18,19,23].
Lynch-like syndrome is HNPCC condition associated with CRC tumors with 
two somatic mutations in one of the MMR genes in the tumor, but no germline 
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mutations. Although these cases are not hereditary, the tumors manifest MSI and 
immunohistochemically absence of a MMR protein. Limited published data sugge-
sts that Lynch-like syndrome patients have a similar age of onset of CRC but lower 
incidence of extra-colonic cancers compared to patients with Lynch syndrome [4,24].
Familial colorectal cancer type X (FCCTX) is HNPCC condition associated with 
CRC tumors negative for MSI and germline mutations in MMR genes. Clinically, 
FCCTX is associated with a twofold increased risk of CRC compared to the general 
population but without an increased risk of extra colonic cancers [4,22,23].
Polymerase proofreading associated polyposis syndrome (PPAP) is a rare auto-
somal dominantly inherited syndrome in which the exonuclease domain of POLE 
(encoding DNA polymerase e) or POLD1 (encoding DNA polymerase d1) is mutated 
in the germline. Two highly penetrant mutations are described (POLE p.Leu424Val 
and POLD1 p.Ser478Asn) [25]. Individuals with germline POLE mutations exhibit 
colonic oligopolyposis (generally between 5-70 adenomas) as early as 20 years of 
age, CRCs, and duodenal adenomas and carcinomas. POLD1 mutation carriers exhi-
bit colonic oligopolyposis (generally 3-50 adenomas) and CRC as young as 20 years 
of age as well, but in addition exhibit increased risk for endometrial cancers and 
brain tumors [19,25]. Although CRCs from PPAP patients are hypermutated or ul-
tramutated due to loss of polymerase function these tumors are microsatellite stable 
and do not exhibit loss of expression of MMR proteins [10,25].
The opportunity to prevent the occurrence of and mortality from hereditary 
colorectal cancer is maximized by the recognition of clinical features of each syn-
drome, an accurate risk assessment with genetic testing and appropriate screening 
and surveillance. Collaboration between primary care providers, gastroenterologi-
sts, colorectal and other surgeons, pathologists, oncologists, and genetic specialists 
is the optimal approach to care for patients and families with hereditary colorectal 
cancer [23].
Modern molecular platforms give the ability to characterize tumors at multiple 
levels and to define molecular and biological subtypes of cancer. Cancers could be 
divided into subtypes that are more or less aggressive. Identification of a more ag-
gressive subtype may influence the type of their treatment. Molecular stratification 
and sub classification of tumors will add a step to traditional clinical practice and 
better diagnosis and therapy of different types of cancer as well as colorectal cancer 
[26].
Optimization of molecular genetic testing to predict the risk for developing can-
cer, to diagnose a disease at an early stage, to give a prognosis, and predict treatment 
response is of great importance to the patients as well as to the health professionals.
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Sažetak
Molekularna stratifikacija sporadičnog i nasljednog kolorektalnog karcinoma
Kolorektalni karcinom je jedan od najčešćih zloćudnih tumora i jedan od vodećih uzroka 
smrti od raka u zemljama razvijenog svijeta. Bolest nastaje kroz duži niz godina tijekom kojih 
kao posljedica mutacija u onkogenima, tumor supresorskim genima i genima za popravak DNA 
iz normalne sluznice kolona preko adenoma nastaje zloćudni metastatski karcinom. Najveći 
broj karcinoma kolorektuma javlja se u sporadičnom obliku dok jedna trećina bolesnika ima 
pozitivnu obiteljsku anamnezu i izložena je povećanom riziku da oboli od ovog zloćudnog 
tumora. Međutim, svega 5% karcinoma kolorektuma nastaje kao posljedica nasljedne mutaci-
je u genu APC ili genima za popravak krivo sparenih baza u DNA (MMR). Najčešći nasljedni 
sindrom karcinoma kolorektuma je sindrom Lynch (LS) koji se nasljeđuje mutacijama u genima 
za popravak DNA. Pojam nasljednog nepolipoznog karcinoma kolorektuma (HNPCC) koji se 
koristio kao sinonim za LS danas se povezuje sa spektrom obiteljskih karcinoma kolorektuma koji 
imaju kliničke karakteristike slične LS, ali oboljeli nisu nosioci nasljednih mutacija MMR gena. 
Razlikovanje nasljednih sindroma objedinjenih pod nazivom HNPCC važno je za kliničare radi 
pravilnog praćenja oboljelih i članova njihovih obitelji jer se isti razlikuju i po sklonosti razvoju 
karcinoma kolorektuma.
U ovom kratkom preglednom radu opisane su molekularno genetičke promjene u spora-
dičnom i nasljednom kolorektalnom karcinomu te molekularna stratifikacija ovog zloćudnog 
tumora s obzirom na nasljednost, stečene mutacije i mikrosatelitnu nestabilnost.
Ključne riječi: karcinom kolorektuma; sporadični; nasljedni; mikrosatelitna nestabilnost.
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